New formulation helps RNA vaccines withstand high temperatures
MIT researchers have reported a formulation intended to address the ultracold storage requirements of RNA vaccines. The vaccines have been effective against COVID-19 and are also being developed for diseases including cancer, but the source does not provide details about the formulation or how well it performs at higher temperatures.
MIT researchers have found a promising way to address the need for ultracold storage for RNA vaccines, according to Phys.org.
RNA vaccines have proved effective against COVID-19 and are being developed for other diseases, including cancer. The source does not provide details about the new formulation or its performance at high temperatures.
THE QUESTIONS THIS EVENT LEAVES BEHIND
What temperatures can the formulation withstand, and for how long?
What evidence supports the formulation’s effectiveness compared with ultracold storage?
What conditions would be required to use the formulation in areas without reliable refrigeration?
How might broader RNA vaccine development affect storage and distribution priorities?
YOUR QUESTION
Does this story leave you with another question?
Send us the question the report did not answer. It may become the next question IAQ investigates.
GLOBAL CURIOSITY MAP · AUGUST 2026